Johnson & Johnson’s recent investments in medical devices helped boost sales, but the company’s total revenue in the first quarter of the year failed to beat Wall Street expectations. Its stock fell 2%to about $144 on Tuesday, following the healthcare giant’s recent quarterly earnings report. The company’s medical device segment experienced the biggest growth in the company during the three months ending March 31, up 4.5% year-over-year to $7.8 billion. Johnson & Johnson said the growth was... Read this story
